Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Biomaterials. 2018 May 26;176:71–83. doi: 10.1016/j.biomaterials.2018.05.041

Fig. 5. THR binding to AAV8 is necessary for THR-mediated enhanced transduction.

Fig. 5

(A) A schematic administration of the AAV8 vectors. Three groups were assigned: AAV8 only, AAV8/0.1 mM THR and AAV8-0.1 mM THR (B) Images were taken for luminescence expression on days 3, 7, 14, and 21 following the AAV8 only, AAV8/0.1 mM THR, and AAV8-0.1 mM THR after a systemic administration. (C) The average liver luciferase signal was calculated for the different groups. (D) Relative luciferase expression level and vector copy numbers in the brain of each group were determined separately. The data of each group represents the average and SD from five mice. ****p < 0.001 compared to the control mice with the AAV8 treatment only.